EMA Says Novo Nordisk To Discontinue Marketing Of Victoza Across EU/EEA By End Of 2026
Sept 5 (Reuters) - European Medicines Agency (EMA):
EMA: NOVO NORDISK WILL DISCONTINUE MARKETING OF VICTOZA ACROSS EU/EEA BY THE END OF 2026 - WEBSITE
EMA: NOVO NORDISK'S VICTOZA MARKETING CESSATION IS FOR COMMERCIAL REASONS & NOT CONSEQUENCE OF ANY SAFETY OR QUALITY RELATED ISSUE
EMA: DISCONTINUATION OF VICTOZA MAY BE A RISK OF SHORT-TERM INTERMITTENT SHORTAGES IN SOME COUNTRIES UNTIL THE PRODUCT IS NO LONGER MARKETED - WEBSITE
Further company coverage: [NOVOb.CO]
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Citi Raises Brent Crude Forecast to $150: Strait of Hormuz Risks Brew, How High Can Oil Prices Rise?

Fed FOMC Preview: No Rate Cuts Become Consensus, Warsh Succession Imminent

Marvell vs. Broadcom: Who Is the More Worthy ASIC Leading Company?

Tesla Stock Forecast: How Much Will TSLA Stock Be Worth in 2030? Can It Hit $3,000?

SanDisk Earnings Preview: AI Storage Drives Performance Surge, Valuations and Risks Rise

Tradingkey






